Results 91 to 100 of about 27,000 (252)
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia +6 more
wiley +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
British Journal of Pharmacology, EarlyView.Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source
PharmaceuticalsChemotherapy-induced cardiotoxicity (CIC) represents a major long-term complication in paediatric oncology patients, with conventional cardioprotective agents providing only limited efficacy.
Alice Pozza +11 more
doaj +1 more source
A comprehensive review of cancer‐induced cardiac wasting
British Journal of Pharmacology, EarlyView.Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena +5 more
wiley +1 more source
Clinical and Translational ScienceDoxorubicin (DOX) is an effective chemotherapeutic agent; however, its use is limited by dose‐dependent cardiotoxicity, which is challenging to detect early with current biomarkers such as NT‐proBNP.
Mohamed S. Dabour +5 more
doaj +1 more source
Chemotherapy Strategies and Their Efficacy for Mesenchymal Chondrosarcoma
Current OncologyMesenchymal chondrosarcoma (MCS) is characterised by small round cell biology, frequent HEY1-NCOA2 fusion, and high vascularity. These features plausibly lessen extracellular matrix barriers and confer relative chemosensitivity.
Piotr Remiszewski +4 more
doaj +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder +7 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam +4 more
wiley +1 more source